Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,270 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Melanoma-targeted chemo-thermo-immuno (CTI)-therapy using N-propionyl-4-S-cysteaminylphenol-magnetite nanoparticles elicits CTL response via heat shock protein-peptide complex release.
Sato A, Tamura Y, Sato N, Yamashita T, Takada T, Sato M, Osai Y, Okura M, Ono I, Ito A, Honda H, Wakamatsu K, Ito S, Jimbow K. Sato A, et al. Among authors: sato m, sato n. Cancer Sci. 2010 Sep;101(9):1939-46. doi: 10.1111/j.1349-7006.2010.01623.x. Cancer Sci. 2010. PMID: 20594194 Free article.
N-propionyl-cysteaminylphenol-magnetite conjugate (NPrCAP/M) is a nanoparticle for the targeted growth suppression of melanoma cells.
Sato M, Yamashita T, Ohkura M, Osai Y, Sato A, Takada T, Matsusaka H, Ono I, Tamura Y, Sato N, Sasaki Y, Ito A, Honda H, Wakamatsu K, Ito S, Jimbow K. Sato M, et al. Among authors: sato a, sato n. J Invest Dermatol. 2009 Sep;129(9):2233-41. doi: 10.1038/jid.2009.39. Epub 2009 Mar 19. J Invest Dermatol. 2009. PMID: 19295615 Free article.
Growth inhibition of re-challenge B16 melanoma transplant by conjugates of melanogenesis substrate and magnetite nanoparticles as the basis for developing melanoma-targeted chemo-thermo-immunotherapy.
Takada T, Yamashita T, Sato M, Sato A, Ono I, Tamura Y, Sato N, Miyamoto A, Ito A, Honda H, Wakamatsu K, Ito S, Jimbow K. Takada T, et al. Among authors: sato a, sato m, sato n. J Biomed Biotechnol. 2009;2009:457936. doi: 10.1155/2009/457936. Epub 2009 Oct 8. J Biomed Biotechnol. 2009. PMID: 19830247 Free PMC article.
Epigenetic silencing of diacylglycerol kinase gamma in colorectal cancer.
Kai M, Yamamoto E, Sato A, Yamano HO, Niinuma T, Kitajima H, Harada T, Aoki H, Maruyama R, Toyota M, Hatahira T, Nakase H, Sugai T, Yamashita T, Toyota M, Suzuki H. Kai M, et al. Among authors: sato a. Mol Carcinog. 2017 Jul;56(7):1743-1752. doi: 10.1002/mc.22631. Epub 2017 Mar 6. Mol Carcinog. 2017. PMID: 28218473
Epigenetic alteration of DNA in mucosal wash fluid predicts invasiveness of colorectal tumors.
Kamimae S, Yamamoto E, Yamano HO, Nojima M, Suzuki H, Ashida M, Hatahira T, Sato A, Kimura T, Yoshikawa K, Harada T, Hayashi S, Takamaru H, Maruyama R, Kai M, Nishiwaki M, Sugai T, Sasaki Y, Tokino T, Shinomura Y, Imai K, Toyota M. Kamimae S, et al. Among authors: sato a. Cancer Prev Res (Phila). 2011 May;4(5):674-83. doi: 10.1158/1940-6207.CAPR-10-0214. Cancer Prev Res (Phila). 2011. PMID: 21543345
Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
Najima Y, Maeda T, Kamiyama Y, Nakao S, Ozaki Y, Nishio H, Tsuchihashi K, Ichihara E, Miumra Y, Endo M, Maruyama D, Yoshinami T, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Ochi N, Kubo T, Uchino K, Kimura T, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T, Yano S. Najima Y, et al. Among authors: sato a. Int J Clin Oncol. 2024 May 17. doi: 10.1007/s10147-023-02461-4. Online ahead of print. Int J Clin Oncol. 2024. PMID: 38755516
Therapeutics Pipeline.
Sauer L, Sato A, Davies HD. Sauer L, et al. Among authors: sato a. Pediatr Clin North Am. 2024 Jun;71(3):481-498. doi: 10.1016/j.pcl.2024.03.002. Pediatr Clin North Am. 2024. PMID: 38754937 Review.
5,270 results